Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

IL-1β expression in IgM monoclonal gammopathy and its relationship to multiple myeloma

Leukemia volume 16, pages 382–385 (2002)Cite this article

Abstract

We have shown that IL-1β is not detectable in normal plasma cells but is produced by plasma cells from virtually all patients with multiple myeloma (MM). To extend our earlier work, IL-1β expression was determined in 13 newly diagnosed patients with IgM monoclonal gammopathy. Eleven patients with Waldenstrom's macroglobulinemia (WM) and two patients with IgM MM were investigated for IL-1β expression by in situ hybridization (ISH). All patients with WM had bone marrow biopsies consistent with the diagnosis, an IgM M-protein in the serum, and subsequently required chemotherapy. Seven of 11 patients with WM had an M-protein >3 g/dl and five patients had bone surveys performed that were negative for osteolytic disease. Two patients were diagnosed with IgM MM because of the presence of significant osteolytic disease on a metastatic bone survey. ISH for kappa, lambda, and IL-1β expression was performed on bone marrow aspirates from each of the 13 patients. None of the neoplastic cells from the 11 patients with WM showed detectable IL-1β expression by ISH. However, the neoplastic cells from both patients with IgM MM expressed IL-1β mRNA at high levels. This aberrant IL-1β production may explain the presence of bone lesions in the patients with IgM MM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Donovan KA, Lacy MQ, Kline MP, Ahmann GJ, Heimbach JK, Kyle RA, Lust JA . Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma Leukemia 1998 12: 593–600

    Article  CAS  Google Scholar 

  2. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA . Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma Blood 1999 93: 300–305

    CAS  PubMed  Google Scholar 

  3. Lust JA, Donovan KA . The role of interleukin-1 beta in the pathogenesis of multiple myeloma Hematol Oncol Clin North Am 1999 13: 1117–1125

    Article  CAS  Google Scholar 

  4. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T . Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers FASEB J 1995 9: 899–909

    Article  CAS  Google Scholar 

  5. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA . Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1) J Immunol 1986 137: 245–254

    CAS  PubMed  Google Scholar 

  6. Terry RW, Kwee L, Levine JF, Labow MA . Cytokine induction of an alternatively spliced murine vascular cell adhesion molecule (VCAM) mRNA encoding a glycosylphosphatidylinositol-anchored VCAM protein Proc Natl Acad Sci USA 1993 90: 5919–5923

    Article  CAS  Google Scholar 

  7. Torcia M, Lucibello M, Vannier E, Fabiani S, Miliani A, Guidi G, Spada O, Dower SK, Sims JE, Shaw AR, Dinarello CA, Garaci E, Cozzolino F . Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors Exp Hematol 1996 24: 868–874

    CAS  PubMed  Google Scholar 

  8. Yamamoto I, Kawano M, Sone T, Iwato K, Tanaka H, Ishikawa H, Kitamura N, Lee K, Shigeno C, Konishi J . Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells Cancer Res 1989 49: 4242–4246

    CAS  PubMed  Google Scholar 

  9. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I . The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma Br J Haematol 1990 74: 424–431

    Article  CAS  Google Scholar 

  10. Kyle RA, Lust JA . Monoclonal gammopathies of undetermined significance Semin Hematol 1989 26: 176–200

    CAS  PubMed  Google Scholar 

  11. Kyle RA . Multiple myeloma: review of 869 cases Mayo Clin Proc 1975 50: 29–40

    CAS  PubMed  Google Scholar 

  12. Krausz Y, Zlotnick A . Macroglobulinemia of Waldenstrom associated with severe osteolytic lesions Acta Haematol 1977 58: 307–311

    Article  CAS  Google Scholar 

  13. Leb L, Grimes ET, Balogh K, Merritt JA Jr . Monoclonal macroglobulinemia with osteolytic lesions: a case report and review of the literature Cancer 1977 39: 227–231

    Article  CAS  Google Scholar 

  14. Berman HH . Waldenstrom's macroglobulinemia with lytic osseous lesions and plasma-cell morphology. Report of a case Am J Clin Pathol 1975 63: 397–402

    Article  CAS  Google Scholar 

  15. Kyle RA, Lust JA . The monoclonal gammopathies (paraproteins) Adv Clin Chem 1990 28: 145–218

    Article  CAS  Google Scholar 

  16. Sati HI, Greaves M, Apperley JF, Russell RG, Croucher PI . Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma Br J Haematol 1999 104: 350–357

    Article  CAS  Google Scholar 

  17. Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Guglielmo R . Production of interleukin-1 by bone marrow myeloma cells Blood 1989 74: 380–387

    CAS  PubMed  Google Scholar 

  18. Bataille R, Jourdan M, Zhang XG, Klein B . Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias J Clin Invest 1989 84: 2008–2011

    Article  CAS  Google Scholar 

  19. Du Villard L, Guiguet M, Casasnovas RO, Caillot D, Monnier-Zeller V, Bernard A, Guy H, Solary E . Diagnostic value of serum IL-6 level in monoclonal gammopathies (see comments) Br J Haematol 1995 89: 243–249

    Article  CAS  Google Scholar 

  20. Emile C, Fermand JP, Danon F . Interleukin-6 serum levels in patients with multiple myeloma (see comments) Br J Haematol 1994 86: 439–440

    Article  CAS  Google Scholar 

  21. Nachbaur DM, Herold M, Maneschg A, Huber H . Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters Ann Hematol 1991 62: 54–58

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grant CA62242 from the National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA

    KA Donovan, MQ Lacy, MA Gertz & JA Lust

Authors
  1. KA Donovan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. MQ Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. MA Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. JA Lust
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donovan, K., Lacy, M., Gertz, M. et al. IL-1β expression in IgM monoclonal gammopathy and its relationship to multiple myeloma. Leukemia 16, 382–385 (2002). https://doi.org/10.1038/sj.leu.2402374

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402374

Keywords

This article is cited by

Search

Advanced search

Quick links